Cyrano Therapeutics Announces the Appointment of John Kollins to its Board of Directors

Rhea-AI Summary

Cyrano Therapeutics announced the appointment of John Kollins to its board of directors. Kollins, currently President and CEO of Satsuma Pharmaceuticals (Nasdaq: STSA), brings over 30 years of biopharmaceutical experience. His expertise includes strategic and operational roles, particularly in developing intranasal therapies. Cyrano focuses on treating long-term smell and flavor loss, a condition affecting 5% of the U.S. population, exacerbated by COVID-19. The company previously raised $12.8M in Series A financing to support its development efforts.

Positive

• John Kollins appointed to the board, potentially enhancing strategic direction and expertise.
• Kollins' extensive experience in biopharmaceuticals aligns with Cyrano's focus on intranasal therapies.

Negative

• None.

DELRAY BEACH, Fla., Nov. 9, 2021 /PRNewswire/ -- Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy to restore smell and flavor function, today announced that it has appointed biopharmaceutical industry veteran John Kollins to its board of directors. Kollins is currently President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc.  (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine currently in Phase 3 trials.

"We are excited to welcome John to our board of directors," stated Rick Geoffrion, Chief Executive Officer of Cyrano. "With his extensive strategic, operational and financial expertise in clinical-stage biopharmaceutical companies, including those developing intranasal therapies and treatments for neurological disorders, he brings a valuable perspective to Cyrano as we advance our therapy for the restoration of the lost senses of smell and flavor through Phase 2 development."

Kollins' biopharmaceutical industry experience spans more than 30 years and includes serving as CEO, on board of directors, and in executive leadership positions concerning operations, strategy, business/corporate development and product development and in commercialization roles in discovery, clinical and commercial-stage public and private companies.

Prior to co-founding Satsuma in 2016, he served as Chief Business Officer and Senior Vice President at Transcept Pharmaceuticals, a publicly-traded, neuroscience-focused specialty pharmaceuticals company. He also served successively as Chief Business Officer, Chief Operating Officer and Chief Executive Officer and a member of the board of directors at OXiGENE, Inc., a publicly-traded oncology and ophthalmology company. Earlier he served in business/corporate development and product management roles of increasing responsibility at CovX, Renovis, Elan Pharmaceuticals / Athena Neurosciences and Immunex Corporation.  He received a B.S.E. degree from Duke University and an M.B.A. from the University of Virginia's Darden School of Business

"I am very pleased to join the Cyrano Therapeutics board of directors," commented Kollins, "and I look forward to working closely with the company's board and management on their mission to address this important unmet patient need. Patients suffering long term smell and flavor loss are effectively without 2 of the 5 senses we have as human beings, and tragically COVID-19 has significantly increased the prevalence of this condition and the need for effective therapies."

About Cyrano Therapeutics
Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company developing a novel therapy to restore smell and flavor function. The chronic loss of smell and flavor is a condition affecting at least 5% of the U.S. population with a similar incidence in Europe and Asia. Influenza, allergic rhinitis and traumatic brain injury are commonly known causes of chronic smell and flavor loss. The condition is now recognized as a widely prevalent long-term condition suffered by many patients who have recovered from COVID-19. The company raised a $12.8M Series A financing in December 2020 led by Remiges Ventures and Lumira Ventures.  www.cyranotherapeutics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cyrano-therapeutics-announces-the-appointment-of-john-kollins-to-its-board-of-directors-301420237.html

SOURCE Cyrano Therapeutics

FAQ

Who is John Kollins and what is his role at Satsuma Pharmaceuticals (STSA)?

John Kollins is the President and CEO of Satsuma Pharmaceuticals, a clinical-stage biopharmaceutical company developing treatments for migraines.

What expertise does John Kollins bring to Cyrano Therapeutics?

Kollins brings over 30 years of biopharmaceutical experience, including roles in strategic operations and product development, especially in intranasal therapies.

How does the appointment of John Kollins impact Cyrano Therapeutics?

Kollins' appointment is expected to enhance Cyrano's strategic direction, leveraging his expertise as the company advances its therapy for smell and flavor restoration.

What condition does Cyrano Therapeutics aim to address with its new therapy?

Cyrano aims to restore the loss of smell and flavor, a condition affecting approximately 5% of the U.S. population, worsened by COVID-19.

How much funding did Cyrano Therapeutics raise in its Series A financing?

Cyrano Therapeutics raised $12.8 million in Series A financing in December 2020 to support its development efforts.